Medical Data Vision Co.Ltd. (JP:3902)
:3902
Top Page
Medical Data Vision Co.Ltd.
(3902)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥1,789.00
▲(5.98% Upside)
Action:ReiteratedDate:02/11/26
The score is supported primarily by a strong, low-risk balance sheet and a recovering (but still volatile) financial profile. This is tempered by a stretched technical condition (RSI > 80) and especially by a very high P/E multiple, which increases downside sensitivity if earnings improvement does not continue.
Positive Factors
No debt; conservatively positioned balance sheet
Zero reported debt materially reduces financial risk and gives the company flexibility to fund product development, M&A or weather downturns without refinancing pressure. This durable capital structure supports multi‑year strategy execution and resilience to earnings volatility.
Negative Factors
Operating profitability collapsed in 2024
A sharp collapse in operating profitability followed by only partial recovery signals structural sensitivity of margins to cost allocation, project timing or pricing pressure. Persistent thin operating margins reduce ability to self‑fund growth and amplify earnings risk.
Read all positive and negative factors
Positive Factors
Negative Factors
No debt; conservatively positioned balance sheet
Zero reported debt materially reduces financial risk and gives the company flexibility to fund product development, M&A or weather downturns without refinancing pressure. This durable capital structure supports multi‑year strategy execution and resilience to earnings volatility.
Read all positive factors
Medical Data Vision Co.Ltd. (3902) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥65.67B
Dividend Yield0.39%
Average Volume (3M)221.94K
Price to Earnings (P/E)228.0
Beta (1Y)0.12
Revenue Growth6.17%
EPS Growth-8918.66%
CountryJP
Employees315
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)5.94
Shares Outstanding40,027,527
10 Day Avg. Volume317,960
30 Day Avg. Volume221,940
Financial Highlights & Ratios
PEG Ratio-1.68
Price to Book (P/B)20.73
Price to Sales (P/S)9.77
P/FCF Ratio88.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)19.3
Revenue Forecast (FY)¥8.60B
Medical Data Vision Co.Ltd. Business Overview & Revenue Model
Company Description
Medical Data Vision Co., Ltd. develops, produces, maintains, and sells medical information integration systems in Japan. The company also offers medical data analysis, survey, and consulting services; management consulting services for medical ins...
How the Company Makes Money
Medical Data Vision Co., Ltd. makes money primarily through the sale and subscription of its healthcare IT solutions. The company's key revenue streams include licensing fees for its software products, subscription fees for its cloud-based service...
Medical Data Vision Co.Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
86
Very Positive
Cash Flow
65
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.16B | 6.54B | 5.91B | 6.42B | 6.10B | 5.67B |
| Gross Profit | 4.40B | 4.55B | 4.33B | 5.03B | 5.03B | 4.64B |
| EBITDA | 88.91M | 174.77M | 130.00M | 1.87B | 1.91B | 1.73B |
| Net Income | -715.18M | 280.24M | -791.17M | 979.13M | 870.51M | 1.09B |
Balance Sheet | ||||||
| Total Assets | 4.63B | 4.78B | 4.75B | 6.23B | 4.91B | 5.53B |
| Cash, Cash Equivalents and Short-Term Investments | 1.83B | 1.71B | 1.35B | 3.22B | 2.26B | 3.22B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.80B | 1.67B | 1.59B | 1.91B | 1.30B | 1.33B |
| Stockholders Equity | 2.80B | 3.08B | 3.10B | 4.25B | 3.52B | 4.16B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 719.83M | -1.03B | 1.59B | 857.55M | 1.06B |
| Operating Cash Flow | 0.00 | 782.21M | -877.85M | 1.62B | 910.79M | 1.08B |
| Investing Cash Flow | 0.00 | -96.93M | -592.97M | -437.83M | -868.75M | -26.93M |
| Financing Cash Flow | 0.00 | -319.33M | -399.00M | -225.26M | -979.36M | -1.03B |
Medical Data Vision Co.Ltd. Technical Analysis
Positive
1688.00
Price Trends
1682.70
Positive
1364.19
Positive
932.85
Positive
Market Momentum
4.42
Positive
66.88
Neutral
59.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3902, the sentiment is Positive. The current price of 1688 is above the 20-day moving average (MA) of 1682.65, above the 50-day MA of 1682.70, and above the 200-day MA of 932.85, indicating a bullish trend. The MACD of 4.42 indicates Positive momentum. The RSI at 66.88 is Neutral, neither overbought nor oversold. The STOCH value of 59.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3902.
Medical Data Vision Co.Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥1.12T | 18.91 | 12.15% | 1.01% | 33.50% | 17.26% | |
63 Neutral | ¥65.67B | 228.03 | ― | 0.39% | 6.17% | -8918.66% | |
63 Neutral | ¥233.94B | 26.76 | ― | 0.43% | 20.55% | 48.62% | |
52 Neutral | ¥7.90B | 33.39 | ― | ― | 41.16% | 2750.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥69.14B | 77.03 | 5.76% | ― | 31.95% | -40.95% | |
44 Neutral | ¥2.79B | -4.28 | ― | ― | 16.19% | -4.42% |
* Healthcare Sector Average
JP:3902
Medical Data Vision Co.Ltd.
1,684.00
1,292.00
329.59%
JP:2413
M3
1,645.00
0.53
0.03%
JP:4480
Medley
2,112.00
-1,013.00
-32.42%
JP:4438
Welby Inc.
337.00
52.00
18.25%
JP:4483
JMDC Inc.
3,575.00
684.56
23.68%
JP:9218
Mental Health Technologies Co. Ltd.
756.00
17.54
2.38%
Medical Data Vision Co.Ltd. Corporate Events
Medical Data Vision Reports Strong Financial Turnaround for 2025
Nov 14, 2025
Medical Data Vision Co., Ltd. reported a significant turnaround in its financial performance for the nine months ending September 30, 2025, with net sales increasing by 12.7% year-on-year to 4,650 million yen. The company achieved a net income of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.